A Republican bill with no cosponsors
Last activity — Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
In committee
Introduced and handed to a committee in the chamber it started in.
The committee holds it, and most bills are never heard from again. A hearing or a committee vote would be news; silence is the usual outcome, and it kills the bill without anyone voting against it.
Its path through Congress
- Introduced
- In Committee
What this bill would do
This bill is called the Most Favored Patient Act of 2026. It requires the Center for Medicare and Medicaid Innovation to test a Most Favored Nations Pricing Model starting on January 1, 2029. Under this model, drug manufacturers must provide access to the most-favored-nation price for certain covered drugs to eligible individuals and healthcare providers. The pricing model will be carried out for a period of 5 years. The bill also allows the Secretary to suspend these requirements if a manufacturer enters into a covered agreement that includes increasing manufacturing operations in the United States.
Yes· 3 of 12
- Scored +8
Does this lower the price of prescription medicines?
The bill requires the implementation of a most-favored-nation pricing model to lower covered prescription drug costs for eligible individuals.
- Scored +7
Would people over 65 be better off under this?
Seniors enrolled in Medicare Part D or Part B will benefit from lower, international reference-based drug prices.
- Scored +7
Would retired people be better off under this?
Retirees on Medicare will experience significant savings on covered prescription drugs.
The opposite
- Scored -2
Would business owners be better off under this?
Pharmaceutical manufacturers face potential price controls and mandated pricing models under the legislation.
Who it would affect, and how
Potential Positive Impacts for People
-
Section 2, adding subsection (h)(1)(A): Eligible individuals and healthcare providers may get access to the most-favored-nation price for covered drugs, which is defined as the second-lowest applicable net price found in specific reference countries. This could help lower the cost of prescription drugs for people who rely on Medicare or Medicaid.
-
Section 2, adding subsection (h)(2) and subsection (h)(4)(C): Manufacturers can enter into agreements to commit to increasing manufacturing operations in the United States. This could potentially create domestic jobs and boost local manufacturing.
Potential Negative Impacts for People
The provided text does not explicitly detail any negative consequences or burdens for individuals or groups of people in the United States.
Groups and Interests Ranking
Every group the model scored this bill for, from -10 to +10. Tap or hover a score for the reason it gave.
- Demographic And Interest Groups
- Would retired people be better off under this? — Retirees on Medicare will experience significant savings on covered prescription drugs. Would people over 65 be better off under this? — Seniors enrolled in Medicare Part D or Part B will benefit from lower, international reference-based drug prices. Would households on low incomes be better off under this? — Low-income individuals covered by Medicaid will see reduced out-of-pocket costs for applicable prescription drugs. Would people with disabilities be better off under this? — Individuals with disabilities who rely on Medicaid or Medicare for prescription drugs will benefit from lower costs. Would middle-income households be better off under this? — Middle-class families with Medicare-eligible seniors will experience financial relief from lower drug costs. Would business owners be better off under this? — Pharmaceutical manufacturers face potential price controls and mandated pricing models under the legislation.
- Healthcare
- Does this lower the price of prescription medicines? — The bill requires the implementation of a most-favored-nation pricing model to lower covered prescription drug costs for eligible individuals. Does this make health care easier to get in general? — Eligible Medicare and Medicaid beneficiaries gain better financial access to lower-priced prescription drugs.
- Economy And Finance
- Is this likely to create jobs? — The bill encourages manufacturers to increase domestic manufacturing operations through covered agreements. Is this likely to grow the economy? — Encouraging domestic drug manufacturing can provide a modest boost to the domestic industrial sector.
- Governance And Ideology
- Does this make what the government does easier for the public to see? — The bill requires reporting of international net prices and agreements to appropriate congressional committees. Does this give the federal government more power? — The legislation expands federal administrative authority through CMS innovation testing and drug pricing requirements.
- Social Issues And Justice
- Is this likely to lift people out of poverty? — Lower prescription drug expenses can ease financial burdens for low-income individuals on Medicare or Medicaid.
- 3/5/2026
- Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- Introduced in House